ESC 365 - Lower risk of atrial fibrillation development associated with SGLT-2 inhibitors in type 2 diabetic patients compared to DPP-4 inhibitors: a nationwide cohort study

ESC Professional Premium Access

Lower risk of atrial fibrillation development associated with SGLT-2 inhibitors in type 2 diabetic patients compared to DPP-4 inhibitors: a nationwide cohort study

Session: Remodelling, prognosis, and outcomes in atrial fibrillation

Topic: Prevention

Speaker: Doctor J. Lee (Cheongju, KR)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Junyoung Lee

Chungbuk National University Hospital, Cheongju (Korea (Republic of))

0 follower

7 more presentations in this session

Duration of left and right atrial activation wavefront assessed non-invasively is significantly higher in patients with atrial fibrillation than in controls.

Speaker: Doctor L. Parreira (Setubal, PT)

The risk and cause of death according to prevalent atrial fibrillation and the role of CHA2DS2-VASc score to stratify the risk of all-cause and cardiovascular death

Speaker: Doctor Y. Kim (Seoul, KR)

Baseline demographic and clinical characteristics as predictors of adverse outcomes to improve management of patients with AF receiving edoxaban: a subanalysis of the ETNA-AF registry

Speaker: Doctor D. Morrone (Pisa, IT)

Impact of atrial fibrillation burden on longitudinal changes in left ventricular structure and function: a post-hoc analysis of a randomized clinical trial

Speaker: Miss F. Vyff (Gentofte, DK)

Prognostic significance of thyroid disease in atrial fibrillation

Speaker: Doctor A. Papazoglou (Athens, GR)

Access the full session

Remodelling, prognosis, and outcomes in atrial fibrillation

Speakers: Doctor J. Lee, Doctor L. Parreira, Doctor Y. Kim, Doctor D. Morrone, Miss F. Vyff...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources